Anemia.
Turner J, Parsi M, Badireddy M.
2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
Rubrometabolic Syndrome.
Kalra S, Coetzee A, Kalra PA, Saldaña JR, Kilov G.
Minerva Endocrinol (Torino). 2023 Mar;48(1):59-75. doi: 10.23736/S2724-6507.20.03353-2. Epub 2020 Dec 17.
Erythropoietin.
Jelkmann W.
J Endocrinol Invest. 2003 Sep;26(9):832-7. doi: 10.1007/BF03345232.
Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.
Charles S, Süssenberger R, Settje T, Langston C, Lainesse C.
J Vet Intern Med. 2024 Jan-Feb;38(1):197-204. doi: 10.1111/jvim.16807. Epub 2023 Sep 22.
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease.
Haase VH, Tanaka T, Koury MJ.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):409-418. doi: 10.1182/hematology.2024000655.
Neuropathology of cerebrovascular diseases.
Ferrer I, Vidal N.
Handb Clin Neurol. 2017;145:79-114. doi: 10.1016/B978-0-12-802395-2.00007-9.
Anemia in chronic kidney disease.
Atkinson MA, Warady BA.
Pediatr Nephrol. 2018 Feb;33(2):227-238. doi: 10.1007/s00467-017-3663-y. Epub 2017 Apr 15.
Hypoxic, anemic and cardiac hypoxemia: When does tissue hypoxia begin?
Köhler D, Voshaar T, Stais P, Haidl P, Dellweg D.
Dtsch Med Wochenschr. 2023 Apr;148(8):475-482. doi: 10.1055/a-2007-5450. Epub 2023 Mar 29.
The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review.
Waheed YA, Liu J, Almayahe S, Sun D.
Front Nephrol. 2024 Dec 23;4:1511596. doi: 10.3389/fneph.2024.1511596. eCollection 2024.
Stress Erythropoiesis Model Systems.
Bennett LF, Liao C, Paulson RF.
Methods Mol Biol. 2018;1698:91-102. doi: 10.1007/978-1-4939-7428-3_5.
